March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
AAV Mediated Systemic Low Molecular Weight Drug Delivery To The Retina
Author Affiliations & Notes
  • Matthew Campbell
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Marian M. Humphries
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Anna-Sophia Kiang
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Anh T. Nguyen
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Paul F. Kenna
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Peter Humphries
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Footnotes
    Commercial Relationships  Matthew Campbell, None; Marian M. Humphries, None; Anna-Sophia Kiang, None; Anh T. Nguyen, None; Paul F. Kenna, None; Peter Humphries, None
  • Footnotes
    Support  Science Foundation Ireland (SFI), Health Research Board of Ireland (HRB), Fighting Blindness Ireland
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4162. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Matthew Campbell, Marian M. Humphries, Anna-Sophia Kiang, Anh T. Nguyen, Paul F. Kenna, Peter Humphries; AAV Mediated Systemic Low Molecular Weight Drug Delivery To The Retina. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4162.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : It has been estimated that up to 98% of systemically-deliverable low molecular weight anti-neovascular and neuroprotective drugs, many of which would have significant therapeutic potential in the treatment of degenerative retinal conditions, are prevented from entering the retina via the peripheral circulation because of the presence of the inner blood-retina barrier (iBRB). We have recently reported an experimental platform in rodents for non-invasive systemic drug delivery to the retina based on transient RNAi-mediated suppression of transcripts encoding claudin-5, a component of the tight junctions of the inner retinal vasculature. This process allows passive diffusion of clinically validated drugs from the peripheral circulation into the retina while excluding larger potentially harmful substances, and we have used it to radically improve vision in a range of animal models.

Methods: : An AAV-2/9 vector was generated with a doxycycline inducible gene expressing claudin-5 shRNA. The system was tested via intra-vitreal and sub-retinal delivery routes and phenpotype assessments were made using electro-retinography (ERG) and magnetic resonance imaging (MRI).Extent of barrier modulation was assessed in animal models of wet AMD, and Retinitis pigmentosa and systemic delivery of anti-neovascular agents and neuro-protective agents was assessed.

Results: : We report herein on the use of barrier modulation in tandem with systemic drug therapy to prevent retinal degeneration in animal models of Retinitis pigmentoda (RP) and to suppress laser-induced-choroidal-neovascularisation (CNV). These observations constitute the basis of a minimally invasive systemic therapeutic modality for retinal diseases, including RP and AMD, where, in early stage disease, the iBRB is intact and impervious to systemically administered drugs.

Conclusions: : AAV mediated modulation of the iBRB for the purposes of systemic drug delivery to the retina of low molecular weight drugs has the potential to radically improve the chronic treatment of the most common forms of retinal degeneration. Levels of active compound needed to produce a therapeutic effect can also be decreased significantly.

Keywords: gene transfer/gene therapy • retinal degenerations: cell biology • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×